Citigroup Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price

Royalty Pharma (NASDAQ:RPRX) had its price objective upped by Citigroup from $70.00 to $78.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on RPRX. TD Cowen lifted their price target on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. The Goldman Sachs Group reissued a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a report on Thursday, August 6th. Morgan Stanley raised their target price on Royalty Pharma from $65.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Weiss Ratings raised Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, September 14th. Finally, Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 26th. Eight equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $63.29.

Royalty Pharma Trading Up 0.0%

Shares of RPRX stock opened at $67.57 on Thursday. The company’s fifty day simple moving average is $60.71 and its two-hundred day simple moving average is $53.67. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. Royalty Pharma has a 1 year low of $37.31 and a 1 year high of $69.77. The stock has a market capitalization of $38.85 billion, a price-to-earnings ratio of 56.31, a PEG ratio of 1.85 and a beta of 0.37.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.02% and a net margin of 25.68%. The firm had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. As a group, analysts anticipate that Royalty Pharma will post 5.29 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $0.2350 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date is Friday, November 13th. Royalty Pharma’s payout ratio is 78.33%.

Insiders Place Their Bets

In related news, EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares in the company, valued at approximately $15,826,570.53. This trade represents a 27.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of Royalty Pharma stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock valued at $12,324,407 over the last 90 days. Company insiders own 18.84% of the company’s stock.

Institutional Trading of Royalty Pharma

Several institutional investors and hedge funds have recently modified their holdings of RPRX. Maryland State Retirement & Pension System grew its holdings in shares of Royalty Pharma by 15.0% during the 3rd quarter. Maryland State Retirement & Pension System now owns 26,428 shares of the biopharmaceutical company’s stock valued at $1,542,000 after purchasing an additional 3,449 shares during the last quarter. Ritholtz Wealth Management raised its position in Royalty Pharma by 5.7% in the 3rd quarter. Ritholtz Wealth Management now owns 4,955 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 268 shares during the period. Machina Capital S.A.S. raised its position in Royalty Pharma by 59.5% in the 3rd quarter. Machina Capital S.A.S. now owns 47,936 shares of the biopharmaceutical company’s stock worth $2,798,000 after purchasing an additional 17,886 shares during the period. Illinois Municipal Retirement Fund lifted its stake in Royalty Pharma by 0.4% in the third quarter. Illinois Municipal Retirement Fund now owns 199,681 shares of the biopharmaceutical company’s stock worth $11,653,000 after purchasing an additional 786 shares during the last quarter. Finally, Keybank National Association OH lifted its stake in Royalty Pharma by 30.2% in the third quarter. Keybank National Association OH now owns 71,383 shares of the biopharmaceutical company’s stock worth $4,166,000 after purchasing an additional 16,569 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Key Headlines Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Citigroup raised its price target to $78 from $70 and reiterated a Buy rating, citing potential upside from the current share price. TickerReport article
• Positive Sentiment: Royalty Pharma raised its 2026 royalty-receipts outlook to $3.55 billion. The improved forecast may support expectations for continued business growth. RTTNews article
• Positive Sentiment: On an adjusted basis, third-quarter EPS was reported at $1.21, ahead of the $1.18 consensus estimate and up from $1.17 a year earlier. Zacks also reported revenue above its estimate. Zacks article
• Neutral Sentiment: Published earnings summaries show different figures for EPS and revenue, reflecting differing measures or estimates. Investors should distinguish adjusted results from GAAP results when assessing the quarter. Business Insider results
• Negative Sentiment: One report put GAAP EPS at $0.32, below the $1.18 consensus, and revenue at $690.1 million versus an $884.8 million estimate. That reported shortfall could temper optimism about the adjusted earnings beat. MarketBeat earnings report

About Royalty Pharma

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.